98%
Phase II/III failure rate in Alzheimer's over the last two decades
Kim et al., 2022We detect neuroinflammation biomarkers to decide which drug candidate moves forward.
Reproducible, longitudinal pharmacological profiles for CNS drug discovery.
Almost no Alzheimer's drug makes it to approval.
US$ 1.3B
Average cost to bring a drug to market
Wouters et al., 2020US$ 250M/yr
Spent on failing anti-neuroinflammatory trials
Kim, 2022; Cummings et al., 2025A market that keeps growing.
An aging population and regulation that favors human-relevant models.
US$ 27.6B
CNS drug discovery market by 2035
11%
Annual growth (CAGR) 2025-2035
From cellular response to pharmacological profile.
-
1
3D neuroglial model
Astrocytes and microglia in 3D.
-
2
Controlled perturbation
Compound or inflammatory challenge.
-
3
Longitudinal monitoring
Specific biomarkers, tracked over time.
-
4
Auditable profile
Data for go/no-go decisions.
Our science is published, and regulation is moving our way.
Peer-reviewed
Pathological neuroinflammatory conversion of reactive astrocytes is induced by microglia and involves chromatin remodeling.
Villarreal A. et al.
Read the paper
Regulation
FDA Modernization Act 2.0
Opens the door to human-relevant alternatives to animal testing.
From analytical service to data platform.
Pilot studies
Fee-for-service validation.
Recurring screening
Annual batch contracts.
Co-development
Custom, milestone-based.
Data & licensing
Proprietary database access.
Biology to decode the brain. Engineering to put it on a chip.
Want to learn more about our technology?
Talk directly with the founders.